Navigation Links
Genetic Testing Explodes after Supreme Court Patent Decision
Date:8/20/2013

NEW YORK, Aug. 20, 2013 /PRNewswire-iReach/ -- Within weeks of the Supreme Court's historic decision declaring that human genes cannot be patented, two scientists have started a company that will democratize the human genome and give people direct access to their own genetic information – which can have an immediate impact on their health and well being. The court's decision spurred the two scientists, Christopher Mason, PhD, of Weill Cornell Medical College, and Jeffrey Rosenfeld, PhD, of Rutgers Medical School, to form Genome Liberty and begin offering immediate, personalized genetic testing directly to the public – although the results should used in concert with a doctor. 

(Photo:  http://photos.prnewswire.com/prnh/20130820/MN65902)

"The Supreme Court's decision opened an era of genomic liberty, allowing people to look at the DNA for all of their genes – which had been hidden behind patent walls for companies that had a monopoly on such testing," Mason said. "Our next-generation sequencing technology allows individuals to be proactive in understanding how their genome can affect their health decisions."

Previously, individuals had to rely on their doctors to understand their health and to make proper medical decisions for them. As scientists and doctors have found the molecular basis for disease and drug response, it has become increasingly clear that a "one-size-fits-all" framework for medicine is not in patients' best interest.

"Genome Liberty fills an important void in our current medical system," Rosenfeld said. "For example, there are clear genetic markers for many medications that will determine whether a person will respond properly or may have extreme side-effects, including estrogen, codeine, Plavix, Nexium, Prilosec, Zocor, Dilantin, Coumadin, Haloperidol, Abilify, and Celexa.  Such tests are very rarely performed before a drug is prescribed, but they offer distinct advantages.  They overcome most doctors' insufficient understanding of, and even fear of, genetics and genetic testing." 

Genome Liberty will work directly with consumers as well as doctors to offer a Gene-Drug Interaction Test. Here is how the test works:

  • A customer (1) orders the test on the Genome Liberty website; (2) receives a saliva-collection kit; (3) provides a saliva sample; and (4) mails the sample to Genome Liberty's certified medical lab, which extracts the DNA and tests it for the genetic variants corresponding to drug responses.
  • Customers receive a full report within two weeks to bring to their physician, outlining the medications that are recommended and discouraged, based upon an individual's specific genetic profile.

The test costs $99, provides information for a lifetime, and covers dozens of frequently prescribed drugs. It also looks for a condition known as Factor V Leiden that can cause dangerous blood clots when women who have this condition take estrogen, either for birth-control or hormone replacement.  Many of these tests are encouraged by the FDA on the drug label, but they are not widely requested.

"The test provides only immediately useful information," Mason said.  "Many people are wary of having a genetic test performed because they do not want results that will scare them.  Some people do not want to be told that they are at high risk for diseases that are currently untreatable. Genome Liberty's primary focus is on actionable genetic information to help people make smart medical choices."

Genome Liberty's co-founders are established leaders in genetics and the understanding the human genome. Dr. Christopher Mason is a faculty member of the Weill Cornell Medical School and was a witness for the successful plaintiffs in the Supreme Court case.  Dr. Jeffrey Rosenfeld is a faculty member at the Rutgers New Jersey Medical School where his research focuses on human genome variation. He is also a research associate at the American Museum of Natural History.

To learn more about Genome Liberty's mission, go to www.genomeliberty.com or to support their crowdfunding campaign, go to http://www.rockethub.com/29313.

Media Contact: Jeffrey Rosenfeld, Genome Liberty, 917-664-8374, jeff@genomeliberty.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Genome Liberty
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BellBrook Labs Launches Second Generation Transcreener EPIGEN Methyltransferase Assay to Acclerate Epigenetic Drug Discovery
2. Epigenetic and MicroRNA Biomarkers 2013 Market Report
3. Population Genetics Assigns Asymmetric Adaptor Library Construction Patent To New England Biolabs
4. Cytogenetics - Technologies, Markets and Companies - 2013
5. Genetic Engineering: A New Use for Algae in Biofuel Production
6. Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
7. Signal Genetics LLC Announces Update to MyPRS™ Gene Expression Profiling Assay for Multiple Myeloma
8. BellBrook Labs and Tecan Offer Webinar on Screening Epigenetic Targets
9. Todays Technical View: Elan Corp., Amarin, Seattle Genetics, and Cubist Pharma
10. RiboMed and Austrian Institute of Technology Partner on Epigenetic Tests for Early Lung Cancer Detection, Sub-typing and Drug Response
11. Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 Oramed ... ( www.oramed.com ), a ... oral drug delivery systems, announced today that Dr. ... will deliver a presentation titled, "Oral Insulin for ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) ...
(Date:3/22/2017)... 22, 2017 The global chronic ... research report by Transparency Market Research (TMR). The top ... and AbbVie Inc., accounted for a share of only ... in this market are focusing aggressively on mergers, acquisitions, ... is likely to lead to market consolidation in the ...
(Date:3/22/2017)... 22, 2017 /PRNewswire/ - FACIT announced a seed ... "Propellon"), a start-up created by FACIT focused on ... investment, combined with non-dilutive capital, achieves a targeted ... funding enables Propellon to accelerate the nomination of ... financing and/or entering a strategic partnership for clinical ...
(Date:3/22/2017)... 22, 2017   VWR (NASDAQ: ... product and service solutions to laboratory and ... acquired EPL Archives, Inc., an international biorepository ... entire regulated product research, development and commercialization ... and ancillary services. EPL Archives is widely ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Summary This ... understand Merck KGaA and its partnering interests and activities ... Description The Partnering Deals and Alliance since ... activity of one of the world,s leading life sciences ... upon purchase to ensure inclusion of the most up ...
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
(Date:2/26/2017)... Feb. 25, 2017  Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring, announces ... Reentry. "Too often, too many offenders ... county jails are trying to tackle this ongoing ... friends and family members. While significant steps are underway, ...
Breaking Biology News(10 mins):